BridgeBio Pharma Inc vs Enveric Biosciences Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: BridgeBio Pharma Inc is far larger — about 2638.7× Enveric Biosciences Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | ENVB | |
|---|---|---|
Market Cap | $16.36B | $6.20M |
Sector | Health | Health |
52-Week High | $90.17 | $17.40 |
52-Week Low | $47.29 | $1.27 |
Enterprise Value | $18.14B | $1.30M |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →